The HFSA Virtual Annual Scientific Meeting is now OnDemand

Industry Theaters (No CEUs)

Industry Theaters are Non-CME educational activities that allow industry experts to provide clinical updates and educate attendees on current therapies, disease states, products, and pipeline activities. Sessions are formatted for learning and are a great way to receive higher level interaction and engagement with company representatives .Explore the list of Industry Theaters occurring at this year's Annual Scientific Meeting below. These sessions will be held in Industry Theaters A, B, and C in the Virtual Meeting Platform.

Wednesday, September 30

Reverse Cardiac Remodeling in Heart Failure (Medical)
Wednesday, September 30, 2020
4:30 PM – 5:30 PM
Industry Theater A
Faculty: 
James L. Januzzi, Jr., MD
This program highlights the process of cardiac remodeling in heart failure and discusses the potential impact of guideline-directed medical therapy (GDMT) on its reversal. Mechanism and clinical implications of cardiac remodeling are described, along with evidence that reverse cardiac remodeling is associated with improved clincial outcomes in patients with heart failure with reduced ejection fraction. 
Sponsored by Novartis Pharmaceuticals Corporation


The Forgotten Ventricle: The Importance of Protecting the Right Heart
Wednesday, September 30, 2020
4:30 PM – 5:15 PM
Industry Theater B
Faculty: 
Jonathan D. Rich, MD, FACC, FHFSA
Description: 
During this webinar sponsored by Abbott, our expert panel will review innovative strategies related to heart failure management. The webinar will provide an overview of how pulmonary artery pressure monitoring can help to optimize guideline directed medical therapy and advise appropriate timing for advanced therapies across the disease continuum.
Sponsored by Abbott


Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof (Commercial)
Wednesday, September 30, 2020
8:30 PM – 9:30 PM 
Industry Theater A
Faculty: 
Javed Butler, MD, MPH, MBA
Description: 
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
Sponsored by Novartis Pharmaceuticals Corporation


Understanding the Interconnectivity of the CV, Renal, and Metabolic Systems
Wednesday, September 30, 2020
8:30 PM – 9:15 PM 
Industry Theater B
Faculty: 
Jonathan D. Rich, MD, FACC, FHFSA
Description: 
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. / Lilly USA

Thursday, October 1

Thoracotomy Outside the OR: Impact on LVAD Programs and Patients (Commercial)
Thursday, October 1, 2020
4:30 PM – 5:15 PM
Industry Theater A
Faculty: 
Ashwin Ravichandran, MD, PPH, FACC
Description
This session will focus on the impact that a thoracotomy approach has on LVAD programs, patient management, and outcomes.  Topics will include:
•    Patient outcomes with the thoracotomy approach
•    Considerations for post-op management
•    Impact on hospital economics
Sponsored by Medtronic


hATTR Amyloidosis: More than a Mutation (Medical)
Thursday, October 1, 2020
4:30 PM – 5:30 PM
Industry Theater B
Faculty: 
Nitasha Sarswat, MD 
Chafic Karam, MD
Description: 
Please join our expert panel to learn about the importance of recognizing the symptoms of polyneuropathy associated with hATTR Amyloidosis with a focus on V122I mutation, how to distinguish the hallmarks of this polyneuropathy from other common causes in a cardiac population and how to differentiate between neurogenic and non-neurogenic causes of the orthostatic intolerance.
Sponsored by Alnylam Pharmaceuticals


Highlighting Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Knowing the Signs and Symptoms and How to Diagnose and Treat
Thursday, October 1, 2020
8:30 PM – 9:15 PM 
Industry Theater A
Faculty: 
Jose Nativi-Nicolau, MD
Description:
Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a life-threatening, underrecognized, and underdiagnosed disease. This presentation will provide an overview of ATTR-CM, and highlight the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve a differential diagnosis. Illustrative patient cases will be used as examples of assessment through to diagnosis. The program will end with a review of the clinical data for an oral treatment option for ATTR-CM.
Supported by Pfizer


The Cardiac Sarcomere in HFrEF and HCM: From Bedside to Bench (Medical)
Thursday, October 1, 2020
8:30 PM – 9:15 PM
Industry Theater B
Faculty: 
Adrian F. Hernandez, MD, MHS 
David Alan Kass, MD 
Sanjiv J. Shah, MD
Description:
This program will provide an update on contemporary treatment in HFrEF and HCM, reviewing the neurohormonal dysfunction that occur in HFrEF and the functional defects of HCM as the targets of current therapy. The remaining unmet needs from a mechanistic perspective will be discussed, including an overview of the physiology of cardiac myocyte contractility. The basics of myocardial contraction at the level of the sarcomere and the influence of calcium regulation, myocardial energetics, and key proteins actin and myosin on myocardial contractility will be discussed.  Additionally, the program will review how dysregulation of calcium flux, myocardial energetics and actin-myosin interaction plays a central role in the pathophysiology of each disease and, lastly, how calcitropy, mitotropy, and myotropy may modulate contractile function.
Sponsored by Cytokinetics, Inc.

Friday, October 2

IN TOUCH WITH PATIENT NEEDS: A Treatment Option for the Polyneuropathy of Hereditary ATTR Amyloidosis (Commercial)
Friday, October 2, 2020 
4:30 PM – 5:30 PM 
Industry Theater A
Faculty: 
    Richard Wright, MD
    Chafic Karam, MD
Description:
Are your patients with hereditary ATTR amyloidosis also suffering from polyneuropathy? Our expert speakers will discuss the importance of recognizing the disease early and how a treatment option for the polyneuropathy of hereditary ATTR amyloidosis affects neuropathy progression and patient quality of life. We look forward to your participation!
Sponsored by Akcea Therapeutics


Getting to The Heart of Managing Heart Failure Advancements of Clinical Utility of Quality of Life for the HFrEF Patient (Medical)
Friday, October 2, 2020
4:30 PM – 5:30 PM
Industry Theater B
Faculty: 
John A. Spertus, MD, MPH
Description:
Dr Spertus gets to the heart of managing heart failure by providing an overview of the clinical utility of QoL and other PROs and the importance of embracing QoL discussions with patients and caregivers
Sponsored by Amgen Inc.


Getting to The Heart of Managing Heart Failure
1. Different Pathways in HFrEF
2. Addressing Unmet Medical Needs in HFrEF (Medical)
Friday, October 2, 2020
8:30 PM – 9:30 PM
Industry Theater A
Faculty: 
Marco Metra, MD 
John R. Teerlink, MD
Description:
Drs Metra and Teerlink get to the heart of managing heart failure. They provide an overview of Different pathways in HFrEF by focusing on the limitations of the current SoC that primarily target the neurohormonal system. They review unmet medical needs in HFrEF, including considerations for impaired renal function and low blood pressure and symptomatic hospitalized or recently hospitalized patients.
Sponsored by Amgen Inc.


TTRials and TTRibulations: Understanding Healthcare Challenges and Barriers in Underserved ATTR-CM Patients (Medical)
Friday, October 2, 2020
8:30 PM – 9:15 PM
Industry Theater B
Faculty: 
Hanna A. Mazen.  MD
Masri Ahmad, MD, MS
Description:
“TTRials and TTRibulations: Understanding Healthcare Challenges and Barriers in Underserved ATTR-CM Patients” 
 
The program shines a spotlight on disparities of care that may exist in the diagnosis and management of ATTR-CM as they apply to geographical, cultural, and socioeconomic challenges.  These issues are further compounded by the COVID-19 pandemic.  
 
This educational session will:   
1.    Evaluate the disparities that may exist in the context of ATTR-CM
2.    Examine factors potentially contributing to these disparities 
3.    Brainstorm and discuss ways for addressing these disparities
Sponsored by Eidos Therapeutics

Saturday, October 3

5th Annual Symposium Managing the Economic Challenges in the Treatment of Heart Failure (Medical)
Saturday, October 3, 2020
8:30 AM – 9:45 AM
Industry Theater A
Faculty:
Larry A. Allen, MD, MHS 
Nihar R. Desai, MD, MPD 
Ileana L. Pina, MD, MPH. FAHA, FACC
Description:
We invite you to join us on Saturday, October 3, 2020 from 8:30 AM to 9:45 AM EST for the 5th Annual Symposium, “Managing the Economic Challenges in the Treatment of Heart Failure”. Our distinguished faculty will discuss and engage the audience on many issues relevant to the care of patients with heart failure in modern practice. This symposium will provide the audience with an understanding of the current challenges and opportunities as heart failure care moves from volume based to value-based care in the era of increasing therapeutic complexity. In addition, the program will discuss the recent evolution of telehealth and remote care for heart failure from the perspectives of clinicians, patients, and payors, and the impact of remote medicine on clinical outcomes and costs of heart failure management. Finally, the program will conclude with an interactive panel examining the upcoming challenges of managing patients with more complex, severe and costly disease burden. We look forward to a lively and engaging discussion on these important topics; we hope that you will join us in this conversation. 
Sponsored by Cytokinetics, Inc.

Monday, October 5

Hope is Here – A Modern Approach for Heart Failure Treatment (Commercial)
Monday, October 5, 2020
4:30 PM – 5:15 PM 
Industry Theater A
Faculty:
Joyce Wald, DO
Nirav Raval, MD
Rami Kahwash, MD
Emad F. Aziz, MD
Description:
The session will provide a an overview of CCM therapy, a breakthrough technology that is FDA approved and indicated for NYHA Stage III Patients with an EF 25 - 45%, on GDMT, in normal sinus rhythm, are NOT indicated for CRT, but remain symptomatic.  The Optimizer® device was designed to increase the contractility of the heart.  Faculty will discuss cardiac contractility modulation mechanism of action, summarize the clinical trials leading to the FDA-approved therapy, and provide an overview  of the implant procedure as well as a mechanism for patient identification and screening.
Sponsored by Impulse Dynamics USA, Inc.


Acute Decompensated Heart Failure - The Role of Impella® (Commercial)
Monday, October 5, 2020
4:30 PM – 5:15 PM
Industry Theater B
Faculty:
Shelley Hall, MD, FACC, FHFSA, FAST
Description:
Dr. Shelley Hall discusses ADHF and the role of the Impella 5.5® Heart Pump and how Interventionalist and Surgeons are HER world.  During this talk Dr. Hall reviews:
•    The Importance of Shock Etiology
•    The Necessity of Heart Evaluation
•    Treatment Options
•    Impella 5.5 Heart Pump
Sponsored by Abiomed

Tuesday, October 6

To Crush or Not to Crush: Challenges & Risks of Crushing/Compounding Medications In the New Era (Commercial)
Tuesday, October 6, 2020
4:30 PM – 5:15 PM
Industry Theater A
Faculty:
Rob Acetta, RPh, C-MTM, BCGP 
Caroline Stubbs        
Description:
Providers face numerous challenges and risks when it comes to crushing/compounding medications in this new world. Now there are fears of contamination or spreading of COVID-19, as well as ongoing concerns presented by PDPM, USP, NIOSH, OSHA and CMS.

Learn why you need to be aware of the new standards for handling medications in your facility … from ordering to dispensing to disposition, and all the steps in between. See why crushing a pill can put you or your patient at risk. Experienced clinician and educator Rob Accetta will be the featured speaker and present must-hear advice.

Sponsored by CMP Pharma